Shilpa Medicare Q1 FY27 Unaudited Results: Profit Rises, Director Re-appointment Approved
Shilpa Medicare reported strong Q1 FY27 results with standalone net profit at ₹6,492 lakhs and consolidated net profit at ₹10,088 lakhs. The Board approved the re-appointment of Mr. Sharath Reddy Kalakota as Whole-time Director. Shilpa Biocare plans to invest up to EUR 7 million in Gate2Brain. The 39th AGM is scheduled for September 11, 2026.
The substantial increase in profits for the quarter, coupled with strategic investment and directorial changes, are material events that are likely to have a significant impact on the company's performance and investor sentiment.
The company reported significant year-on-year growth in both standalone and consolidated net profits for the quarter ended June 30, 2026. The re-appointment of a key director and a strategic investment further contribute to a positive outlook.
Shilpa Medicare Limited announced the outcome of its Board Meeting held on August 5, 2026. The Board approved the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. For the quarter ended June 30, 2026, standalone net profit was ₹6,492 lakhs, an increase from ₹1,871 lakhs in the previous year. Consolidated net profit attributable to owners of the Parent Company stood at ₹10,088 lakhs for the quarter ended June 30, 2026, compared to ₹4,688 lakhs in the same period last year.
The Board also approved the re-appointment of Mr. Sharath Reddy Kalakota as Whole-time Director, subject to member approval at the ensuing Annual General Meeting (AGM). Mr. Kalakota, with over 3 decades of experience in API manufacturing and project execution, is liable to retire by rotation.
Furthermore, the company disclosed the payment of remuneration to Mr. Madhav Vishnukant Bhutada, Non-Executive Director of Shilpa Biologicals Ltd (SBPL), by way of commission up to 1% of SBPL's net profits effective April 1, 2026.
In strategic developments, Shilpa Biocare Private Limited, a wholly-owned subsidiary, intends to invest up to EUR 7 million in Gate2Brain (G2B) through a combination of cash infusion, equity for services, and development of projects.
The 39th AGM of Shilpa Medicare Limited is scheduled for Friday, September 11, 2026, at 11:00 AM via video conferencing. The record date for determining shareholders entitled to the final dividend for FY 2025-26 and for e-voting is Friday, September 4, 2026. Remote e-voting will commence on September 7, 2026, and conclude on September 10, 2026.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.